AI Chat
Loading data for ICLR — first visit, this takes a few seconds.

ICON Public Limited Company

ICLR · NasdaqGS · USD

172.41 +3.48 (2.06%)

At close: Sep 15, 2026, 8:00 PM

173.31 +0.50%

After-hours: 5:33 PM

Market Cap
$13.31B
Volume
625K
Next earnings date
Oct 21, 2026

ICON Public Limited Company (ICLR) Stock Price, Analysis & Data

Intrinsic Value

Loading intrinsic value…

Analyst Forecast

Stock Forecasts →

Analyst forecast unavailable

12-month target · n/a analysts

Analyst Consensus: n/a

Interval:1D
Loading candles and signals…

Financial Performance

View financials →

Loading...

Latest Earnings

ReportedVs estimateYoY Change
Revenue$2.06Bn/a+1.20%
EPS$2.56+$0.04-21.47%

Next Earnings

after market closes.

Estimate · Upgrade →

View earnings details →

Metrics

Bid
124.42
Net Income (ttm)
27M
1.20
0.64
269.45
14.52
P/B (ttm)
1.42
P/S (ttm)
1.60
Earnings Date
Oct 21, 2026
Ask
217.45
Volume
624,567
Avg. Volume (20D)
825,219
Open
168.02
Previous Close
168.93
Day's Range
167.72 - 172.94
52-Week Range
66.57 - 203.91
Ex-Dividend Date
n/a

About ICON Public Limited Company

View profile →
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland. Diagnostics & Research · Healthcare

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Sector Healthcare
IPO Date May 15, 1998
Employees 40,200
Stock Exchange NasdaqGS
Ticker Symbol ICLR